As Bertagnolli steps in, NIH and FDA reenvision clinical trials and evidence generation

Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology

The Pazdurs in their garden with their dog, Cleo. The dog’s full name is Cleopatra, Queen of Denial.In 1999, Rick Pazdur went in for a “perfunctory” final interview at FDA. Thinking it would only take a few minutes, his wife, Mary, decided to wait and have a quick cup of coffee at a nearby restaurant—Hooters.

Supreme Court lifts lower-court freeze on RIFs

The U.S. Supreme Court has temporarily lifted a lower court’s freeze on the Trump administration’s reductions in force, or RIFs, freeing the government to continue their large-scale restructuring of the federal government.

In the name of “radical transparency,” FDA touts publication of 200 complete response letters

In a move advertised as being in line with FDA’s goal of “radical transparency,” the agency July 10 announced the publication of more than 200 complete response letters.

July 11, 2025

Vol.51 No.27

By Jacquelyn Cobb

Funding Opportunities

NCI, SITC immunotherapy fellowship calls for applications

NCI and the Society for Immunotherapy of Cancer are accepting applications for a one-year fellowship program beginning in July 2026.

July 11, 2025

Vol.51 No.27

Guest Editorial

As cancer scientists, we must change how we engage with the public on the impact of NIH cuts
What the scientific method obscures

We recently had the privilege of contributing to a CBS Sunday Morning story on the ongoing crisis in the federal support for research in general and cancer research in particular.

July 03, 2025

Vol.51 No.26

By George J. Weiner and Elizabeth M. Jaffee

Clinical Roundup

Scientists wipe out aggressive brain cancer tumors by targeting cellular “motors”

A potential treatment for glioblastoma crafted by scientists at The Wertheim UF Scripps Institute renders the deadly brain cancer newly sensitive to both radiation and chemotherapy drugs, and blocks the cancer’s ability to invade other tissue, a new study shows.

July 03, 2025

Vol.51 No.26

As Bertagnolli steps in, NIH and FDA reenvision clinical trials and evidence generation

YOU MAY BE INTERESTED IN

Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology

Supreme Court lifts lower-court freeze on RIFs

In the name of “radical transparency,” FDA touts publication of 200 complete response letters

NCI, SITC immunotherapy fellowship calls for applications

As cancer scientists, we must change how we engage with the public on the impact of NIH cuts
What the scientific method obscures

Scientists wipe out aggressive brain cancer tumors by targeting cellular “motors”

Renew today!

Subscriber content

Never miss an issue!

Login

As Bertagnolli steps in, NIH and FDA reenvision clinical trials and evidence generation

YOU MAY BE INTERESTED IN

Rick and Mary Pazdur on facing “the other side of the stethoscope”A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology

Supreme Court lifts lower-court freeze on RIFs

In the name of “radical transparency,” FDA touts publication of 200 complete response letters

NCI, SITC immunotherapy fellowship calls for applications

As cancer scientists, we must change how we engage with the public on the impact of NIH cutsWhat the scientific method obscures

Scientists wipe out aggressive brain cancer tumors by targeting cellular “motors”

Never miss an issue!

Login

Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology

As cancer scientists, we must change how we engage with the public on the impact of NIH cuts
What the scientific method obscures